WallStreetZenWallStreetZen

NYSE: EBS
Emergent Biosolutions Inc Stock

$2.53-0.06 (-2.32%)
Updated Mar 28, 2024
EBS Price
$2.53
Fair Value Price
N/A
Market Cap
$132.07M
52 Week Low
$1.42
52 Week High
$13.67
P/E
-0.17x
P/B
0.2x
P/S
0.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.05B
Earnings
-$760.50M
Gross Margin
32.8%
Operating Margin
-61.31%
Profit Margin
-72.5%
Debt to Equity
1.81
Operating Cash Flow
-$206M
Beta
1.22
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

EBS Overview

Emergent BioSolutions Inc. is a biopharmaceutical company developing vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and providing medical devices for biodefense purposes. Among the company's products are the controversial BioThrax (Anthrax Vaccine Adsorbed) and Narcan (naloxone) for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals addressing infectious diseases like cholera and typhoid. Emergent BioSolutions was founded on 1998 and is headquartered in Gaithersburg, MD.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EBS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

EBS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EBS is good value based on its book value relative to its share price (0.2x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.19x)
P/B vs Industry Valuation
EBS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EBS due diligence checks available for Premium users.

Be the first to know about important EBS news, forecast changes, insider trades & much more!

EBS News

Valuation

EBS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.17x
Industry
54.21x
Market
44.51x

EBS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.2x
Industry
2.19x
EBS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

EBS's financial health

Profit margin

Revenue
$276.6M
Net Income
-$49.5M
Profit Margin
-17.9%
EBS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EBS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.8B
Liabilities
$1.2B
Debt to equity
1.81
EBS's short-term assets ($679.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EBS's short-term assets ($679.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EBS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EBS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$32.1M
Investing
-$11.4M
Financing
$4.7M
EBS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

EBS vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
EBS$132.07M-2.32%-0.17x0.20x
INCR$123.50M+7.11%N/A0.92x
ZOM$143.07M+1.39%-7.68x0.55x
CRDL$117.28M+0.56%-5.80x4.64x
SCTL$114.15M-0.92%-7.71x1.95x

Emergent Biosolutions Stock FAQ

What is Emergent Biosolutions's quote symbol?

(NYSE: EBS) Emergent Biosolutions trades on the NYSE under the ticker symbol EBS. Emergent Biosolutions stock quotes can also be displayed as NYSE: EBS.

If you're new to stock investing, here's how to buy Emergent Biosolutions stock.

What is the 52 week high and low for Emergent Biosolutions (NYSE: EBS)?

(NYSE: EBS) Emergent Biosolutions's 52-week high was $13.67, and its 52-week low was $1.42. It is currently -81.49% from its 52-week high and 78.17% from its 52-week low.

How much is Emergent Biosolutions stock worth today?

(NYSE: EBS) Emergent Biosolutions currently has 52,203,433 outstanding shares. With Emergent Biosolutions stock trading at $2.53 per share, the total value of Emergent Biosolutions stock (market capitalization) is $132.07M.

Emergent Biosolutions stock was originally listed at a price of $11.70 in Nov 15, 2006. If you had invested in Emergent Biosolutions stock at $11.70, your return over the last 17 years would have been -78.38%, for an annualized return of -8.61% (not including any dividends or dividend reinvestments).

How much is Emergent Biosolutions's stock price per share?

(NYSE: EBS) Emergent Biosolutions stock price per share is $2.53 today (as of Mar 28, 2024).

What is Emergent Biosolutions's Market Cap?

(NYSE: EBS) Emergent Biosolutions's market cap is $132.07M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Emergent Biosolutions's market cap is calculated by multiplying EBS's current stock price of $2.53 by EBS's total outstanding shares of 52,203,433.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.